Updated diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories by National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Vector-Borne Diseases.
          
______________________________________________________________________________________________________________                 
Memorandum 
 
Date: January 13, 2016 
 
From: CDC, Division of Vector-Borne Diseases, Arboviral Diseases and Dengue Branches 
 





Many countries in the Americas now have local transmission of multiple arboviruses that can 
cause febrile illness with rash, myalgia, or arthralgia.  Therefore, laboratory testing has become 
even more important to confirm the etiology of these diseases.  For patients with acute fever, 
rash, myalgia, or arthralgia and have travelled within the previous 2 weeks to an area with 
ongoing transmission, Zika, chikungunya, and dengue virus infections should all be 
considered.  Laboratory evidence of recent chikungunya, dengue, or Zika virus infection is 
generally accomplished by testing serum to detect viral nucleic acid or virus-specific 
immunoglobulin (Ig) M and neutralizing antibodies.  However, serological cross-reactivity is 
strong between Zika and dengue viruses, so emphasis should be placed on molecular detection 
in acute specimens.  Laboratory testing for all of these agents is currently available at CDC and 
several state health departments. 
 
Laboratory assays for acute specimens  
During the first 7 days of these illnesses, viral RNA can often be identified in serum, and RT-
PCR is the preferred test for all three viruses. In addition, for dengue viruses, NS1 antigen can 
be detected by ELISA in acute phase specimens but this assay is not widely available in the US.     
 
Virus-specific IgM antibodies may be detectable >3 days after onset of illness. However, serum 
collected within 7 days of illness onset may not have detectable virus-specific IgM antibodies 
and IgM testing should be repeated on a convalescent-phase sample to rule out infection in 
patients with a compatible clinical syndrome.  IgM antibodies against Zika virus, dengue 
viruses, and other flaviviruses (e.g., yellow fever and West Nile virus) have strong cross-
reactivity possibly generating false positive results in serological tests. 
 
Laboratory assays for convalescent specimens 
IgM antibodies typically persist for months. In patients with a compatible clinical syndrome, 
serum collected more than 8 days after illness onset should be tested by virus-specific IgM 
ELISA and positive results confirmed by testing for neutralizing antibodies.  
 
There is substantial serological cross-reactivity between the flaviviruses and current IgM 
antibody assays cannot reliably distinguish between Zika and dengue virus infections.  
Therefore an IgM positive result in a dengue or Zika IgM ELISA test should be considered 
indicative of a recent flavivirus infection.  Plaque-reduction neutralization tests (PRNT) can be 
  
performed to measure virus-specific neutralizing antibodies and may be able to discriminate 
between cross-reacting antibodies in primary flavivirus infections. For primary flavivirus 
infections, a fourfold or greater increase in virus-specific neutralizing antibodies between 
acute- and convalescent-phase serum specimens collected 2 to 3 weeks apart may be used to 
confirm recent infection. In patients who have been immunized against (e.g., received yellow 
fever or Japanese encephalitis vaccination) or infected with another flavivirus (e.g., West Nile 
or St. Louis encephalitis virus) in the past, cross-reactive antibodies in both the IgM and 
neutralizing antibody assays may make it difficult to identify which flavivirus is causing the 
patient’s current illness. 
 
Laboratory safety 
Zika and dengue viruses are classified as biological safety level (BSL) 2 pathogens while 
chikungunya virus is classified as a BSL-3 agent.  All should be handled in accordance with 
Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidelines and a risk 
assessment performed for each laboratory for the specific procedures utilized.  In particular, 
because chikungunya virus produces such high levels of viremia, serum from suspected 
chikungunya virus cases should be treated as potentially infectious even for serological 
procedures. 
 




Zika, chikungunya, and dengue virus RT-PCR, IgM ELISA, and plaque reduction neutralization 
tests (PRNT) are performed at CDC. The specific tests performed will depend on the timing of 
the specimens relative to illness onset and clinical information as outlined in the algorithm 
figure.  To determine the appropriate testing algorithm and interpret results, please provide 
the date of illness onset, dates of specimen collection, specimen type, description of clinical 
illness, travel history, flavivirus vaccination history, and contact information for the submitter.  
Testing will primarily be performed on serum or CSF but other specimen types, including 
urine, amniotic fluid, and tissues, can be submitted for evaluation of the utility of these 
specimen types. 
 
Within Puerto Rico, please call 787-706-2399 for questions about testing. For submission of 
specimens, please submit a dengue case investigation report (DCIR) for each specimen which 
can be downloaded from: http://www.cdc.gov/dengue/clinicalLab/index.html  
 
For all other states and territories, questions about laboratory testing or sending specimens to 
CDC should be directed tothe Arboviral Diseases Branch on-call epidemiologist at 970-221-
6400. A completed DASH form should accompany submitted specimens. More information 
about submitting specimens to CDC is at: 
http://www.cdc.gov/ncezid/dvbd/specimensub/arboviral-shipping.html.   
 
State Health Department Laboratories  
RT-PCR: The CDC chikungunya virus and Zika virus RT-PCR protocols follow essentially the 
same protocol as the CDC West Nile virus RT-PCR assay. CDC will provide chikungunya and 
Zika virus primer/probe sequences, an RNA-positive control, and chikungunya and Zika virus 
RT-PCR proficiency panels to state laboratories that have demonstrated proficiency at the CDC 
West Nile virus RT-PCR assay.  Dengue virus RT-PCR kits can be ordered online using the 




Zika virus IgM ELISA: The CDC Zika virus IgM ELISA is similar to the CDC West Nile virus 
IgM ELISA assay. State laboratories that have demonstrated proficiency in performing the 
CDC West Nile virus IgM ELISA during the 2015 evaluation can request Zika virus antigen, 
conjugated antibody, and positive control serum for use in the CDC Zika virus IgM ELISA.  
 
For state health departments interested in obtaining the materials described above, please 
contact dvbid@cdc.gov. If your state health department laboratory does not perform the CDC 
West Nile virus RT-PCR assay or IgM ELISA assay, consider sending specimens to CDC or 
using one of the commercial laboratory options described below.  
 
Commercially-available testing 
There are no commercially-available diagnostic assays or kits for Zika virus infection. 
 
There is an FDA approved kit for anti-DENV IgM antibodies which can be purchased (InBios, 
USA). 
 
The following commercial reference laboratories perform testing for chikungunya and dengue 
viruses but none of the assays are FDA-cleared. 
 Focus Diagnostics (http://www.focusdx.com/) performs a chikungunya virus RT-PCR 
and IgM and IgG IFA assays as well as an anti-DENV IgM ELISA.   
 ARUP Laboratories (http://www.aruplab.com/) performs chikungunya virus and 
dengue virus IgG and IgM ELISA testing. 
 Quest Diagnostics (http://www.questdiagnostics.com) performs dengue virus IgG and 
IgM immunoassays. 
 
The following chikungunya virus IgM antibody test kits are available for purchase in the United 
States and provide sensitivity and specificity comparable to that of the CDC assays but not all 
are FDA-cleared:   
 Anti-CHIKV IgM human ELISA kit (Abcam, UK) 
 Anti-CHIKV ELISA (IgM) (Euroimmun, Germany) 
 Anti-CHIKV IIFT (IgM) (Euroimmun, Germany) 
 CHIKjj Detect MAC-ELISA (Inbios, USA) 
 
Reporting 
Dengue, chikungunya, and Zika are nationally notifiable conditions; state health departments 
should report cases to CDC according to standard CSTE case definitions. State health 
departments are requested to report laboratory-confirmed cases of any arbovirus to CDC 
through ArboNET, the national surveillance system for arboviral disease. 
  
 
 
 
